Stay updated with breaking news from Evidence Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On January 11, the Centers for Medicare and Medicaid Services announced a proposal to cover Food and Drug Administration-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease, including aducanumab, under Coverage with Evidence Development (CED) in CMS-approved randomized controlled trials. Currently, aducanumab is the only monoclonal
New York (January 24, 2022)— On January 11th, the Centers for Medicare and Medicaid Services (CMS) announced that it proposes to cover Food and Drug
/PRNewswire/ -- With so much misinformation surrounding the draft National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services...
WASHINGTON, Jan. 19, 2022 /PRNewswire/ -- With so much misinformation surrounding the draft National Coverage Determination (NCD) from the Centers...
Medicare has unveiled a plan to cover a controversial, expensive new Alzheimer’s drug, but has not said how much patients might pay